Increasing Trends of Polypharmacy and Potentially Inappropriate Medication Use in Older Lung Cancer Patients in China: A Repeated Cross-Sectional Study

Fangyuan Tian1,2*, Zhaoyan Chen1, Xi Chen3 and Mengnan Zhao1

1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China, 2Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China, 3Department of Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China

Objectives: Polypharmacy and potentially inappropriate medication (PIM) use are frequent in older lung cancer patients. This study aimed to examine the trends of polypharmacy and PIM use and explore risk factors for PIM use based on the 2019 Beers criteria in older Chinese lung cancer outpatients with multimorbidity.

Methods: A repeated cross-sectional study was conducted using electronic medical data consisting of the prescriptions of older lung cancer outpatients in China from January 2016 to December 2018. Polypharmacy was defined as the use of five or more medications. The 2019 Beers criteria were used to evaluate the PIM use of older cancer outpatients (age ≥65 years), and multivariate logistic regression was used to identify the risk factors for PIM use.

Results: A total of 3,286 older lung cancer outpatients and their prescriptions were included in the study. The prevalence of polypharmacy was 14.27% in 2016, 16.55% in 2017, and 18.04% in 2018. The prevalence of PIM use, according to the 2019 Beers criteria, was 31.94% in 2016, 35.78% in 2017, and 42.67% in 2018. The two most frequently used PIMs in older lung cancer outpatients were estazolam and tramadol. The logistic regression demonstrated that age 75 to 79, polypharmacy, irrational use of drugs, and lung cancer accompanied by sleep disorders, anxiety or depression, or pain were positively associated with PIM use in older lung cancer outpatients.

Conclusion: The prevalence of polypharmacy and PIM use in older lung cancer outpatients with multimorbidity was high in China, and polypharmacy and PIM use increased over time. Further research on interventions rationing PIM use in the older lung cancer patient population is needed.

Keywords: polypharmacy, potentially inappropriate medication, lung cancer, older, outpatient
INTRODUCTION

Lung cancer is the leading cause of cancer death worldwide, accounting for nearly 1.80 million deaths and causing 18% of total cancer deaths in 2020 (Global Cancer Observatory, 2020; WHO, 2022). Older age is associated with cancer development due to biological factors that include DNA damage over time and shortened telomeres. As the population continues to age, the incidence of lung cancer in older patients is expected to further increase in the coming years (Decoster and Schallier, 2019). Approximately 37% of lung cancer cases occur in individuals over 75 years old. Accordingly, the median age at lung cancer diagnosis is 70 years old for both men and women (Torre et al., 2016). The majority of older lung cancer patients have comorbid chronic diseases and must take multiple medications (Grose et al., 2014; Nilsson et al., 2017; Ding et al., 2020). However, increased number of drug-related problems was associated with age-induced alternations in pharmacokinetics (PK) and pharmacodynamics (PD). Lung cancer also affects pharmacokinetics and pharmacodynamics and occurs more frequently in the elderly. Therefore, lung cancer patients who are elderly are more prone to experience adverse drug events. In addition, previous published studies have confirmed that cancer patients are easily exposed to a higher risk of polypharmacy and inappropriate medication use (Wildiers et al., 2014; Koczwara et al., 2022).

Polypharmacy (defined as the use of more than five medicines) is associated with the prescription of inappropriate medications, and extensive studies have demonstrated the link between polypharmacy and negative outcomes (Maddison et al., 2011; Weng et al., 2013; LeBlanc et al., 2015). Potentially inappropriate medication (PIM) use was firstly proposed in 1991 because PIM use brought a series of drug-related problems, such as adverse drug events, hospitalization, and disability, defined as the use of medications that should be avoided, especially when evidence is insufficient or alternative medicines are available (Hyttinen et al., 2016; Muhlack et al., 2017; Wallace et al., 2017).

Some previous reports have examined the trends of polypharmacy and PIM use in older patients (Davidoff et al., 2015; Moriarty et al., 2015; Muhlack et al., 2018). Approximately half of all cancer care is delivered in an outpatient treatment setting (Maleki et al., 2022). It is necessary to investigate the polypharmacy and PIM use in older lung cancer outpatients. However, no study has specifically reported on the trends of polypharmacy and PIM use in older lung cancer outpatients, and the risk factors for PIM use according to the 2019 Beers criteria in older Chinese lung cancer patients are unclear. Therefore, in this study, we extracted data on the prescriptions of older lung cancer outpatients treated at tertiary hospitals in Chengdu, China over 3 years. The trends of the prevalence of polypharmacy and PIM use were calculated, and PIMs were screened based on the 2019 Beers criteria. The risk factors for PIM use were explored. Ideally, this study will provide useful data for follow-up research.

METHODS

Setting and Sample

A repeated cross-sectional study was performed to examine the trends of polypharmacy and PIM use among older lung cancer (histology: non-small-cell lung cancer, small cell lung cancer, unspecified lung cancer; stage: American Joint Commission on Cancer 8th Edition (AJCC) stage I-III) outpatients with multimorbidity that might receive chemotherapy and chronic disease treatment in tertiary hospitals in Chengdu, a capital city in southwest China. The prescriptions of older (aged ≥65) lung cancer outpatients with multimorbidity (cancer with other diseases) were cluster sampled from a cooperative hospital prescription analysis project led by the Chinese Pharmaceutical Association. In this study, cluster sampling was used to randomly select nine hospitals from all tertiary hospitals in Chengdu between 1 January 2016 and 31 December 2018, and then the older lung cancer outpatient prescriptions were selected from all departments of the selected hospitals as the survey samples. Multimorbidity of patients was determined by the numbers of diagnosis in medical record. All data were retrospectively collected without any possibility of individual identification.

Data Collection

In this repeated cross-sectional study, we included older adults with lung cancer attending outpatient department at tertiary care hospitals in Chengdu from 1 January 2016 to 31 December 2018; thus, the prescriptions of 1,002, 1,009, and 1,275 older lung cancer outpatients were included from 2016, 2017, and 2018, respectively. The data were collected by diagnosis type as follows: 1) basic information (region, prescription code, and department source); 2) patient characteristics (age, sex, and diagnosis); and 3) medication characteristics (generic name, trade name, drug specifications, dosage form, administration route, number of prescriptions, prescription expenditure, and frequency of administration). The criteria in the count of prescribed medications are as follows: 1) duration of prescription (≤1 month); 2) route of administration (oral medications, injection medications, topical medications, inhaler, etc.); 3) medications directly related to treatment for lung cancer were counted as concomitant medications (such as oral tyrosine kinase inhibitor or antiemetic for chemo); 4) Chinese traditional herbal medications were not included.

Evaluation Criteria

The 2019 Beers criteria (By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel, 2019) were used to evaluate PIM use in older lung cancer outpatients who were not receiving palliative care or hospice service. The comments about the rationality of prescription were made according to the Chinese Prescription Administrative Policy. The Chinese Prescription Administrative Policy need pharmacists to evaluate the standardization of prescription and the suitability of clinical use of drugs (medication indications, drug selection, route of administration, usage and dosage, drug interaction, incompatibility, etc.) according to relevant regulations, finding existing or potential problems, formulating and implementing intervention and improvement measures to promote the rational application of clinical drugs. Irrational prescriptions were classified as nonstandard prescriptions, inappropriate prescriptions, and supernormal prescriptions referring to...
medication without indications. Any inconsistencies between the two researchers were reviewed by a third professional and then resolved through collective discussion.

**Statistical Analysis**
Categorical data are presented according to frequency, and the χ² test was used to compare categorical variables between groups. Continuous data that were normally distributed are expressed as the mean ± standard deviation (SD), and continuous data that were not normally distributed are expressed as the median (M) and the interquartile range (IQR). Participant sex was categorized as male or female. Age was categorized into four groups: 65–69, 70–74, 75–79, and ≥80 years old, and the number of diseases was divided into three groups: two, three to four, and five or more chronic conditions. For the descriptive analysis, medication use was divided into two strata: the use of one to four medications and the use of five or more medications. Prescriptions were further categorized as rational or irrational. The prescription expenditure was divided into three groups: <500 Chinese yuan, 500–1,000 Chinese yuan, and >1,000 Chinese yuan. Five chronic diseases (sleep disorders, anxiety or depression, pain, pulmonary infection, and chronic obstructive pulmonary disease) were also analyzed. The associations between the risk factors and PIM use (non-PIM use = 0, PIM use = 1) were assessed with a multivariate logistic regression analysis. Statistical analyses were conducted using SPSS version 26.0 (IBM Corp., Armonk, NY). We constructed three models: Model 1 (logistic regression with no adjustment), Model 2 (adjusted for year), and Model 3 (adjusted for year, sex, and age). The results are presented as odds ratios (ORs) and 95% confidence intervals (CIs), and p < 0.05 was considered to be statistically significant.

**Ethics Approval**
This study protocol was approved by the Sichuan University West China Hospital Research Ethics Board (2020/651).

**RESULTS**

**Basic Patient Characteristics**
A total of 3,286 older lung cancer outpatients were included in this study, 55.90% (n = 1,837) of which were male. The median age was 72 (IQR: 68, 76) years old, and age ranged from 65 to 94 years old; the oldest (≥80 years of age) cancer patients accounted for 11.63% (n = 1,153) of the sample. The median number of medical diagnoses was 3 (IQR: 2, 4). The median number of prescriptions was 2 (IQR: 1, 4), and 16.43% (n = 540) of older lung cancer outpatients had polypharmacy. The prevalence of rational prescriptions was 92.64% (n = 3,044), 7.36% (n = 242) had irrational prescription. The characteristics of 242 participants were 60.74% (n = 147) of which were male, the median age was 72 years old and 42.98% (n = 104) of patients had polypharmacy. The median prescription expenditure was 517.90 (IQR: 189.50, 1309.47) Chinese yuan (CNY). In this study, 19.32% (n = 635) of the lung cancer patients had sleep disorders, 3.13% (n = 103) had anxiety or depression, 24.01% (n = 789) had pain, 11.56% (n = 380) had pulmonary infections, and 5.11% (n = 168) had chronic obstructive pulmonary disease (COPD). The basic patient characteristics are provided in Table 1.

**Trends in Older Lung Cancer Outpatients With Multimorbidity**
There were 1,002, 1,009, and 1,275 older lung cancer outpatients with prescriptions included in 2016, 2017, and 2018, respectively. The prevalence of polypharmacy increased from 14.27% (n = 143) in 2016 to 18.04% (n = 230) in 2018. The prevalence of PIM use increased from 31.94% (n = 320) to 42.67% (n = 544) over the 3 years. The number of medications and diseases showed an increasing trend from 2016 to 2018. The prevalence of rational prescriptions increased from 91.22% (n = 914) in 2016 to 93.65% (n = 1194) in 2018, but the average prescription expenditure showed a decreasing trend from 1,260.77 CNY per prescription in 2016 to 1,170.45 CNY per prescription in 2018 (Figure 1).

**Prevalence of PIMs and the Most Frequent PIMs Over the Three Years**
Among the 1,002 older lung cancer outpatients with prescriptions in 2016, 320 (31.94%) outpatients were identified to have at least one PIM, and a total of 428 PIMs were detected according to the 2019 Beers criteria. Of the patients with PIM prescriptions, 80.00% received one PIM, 15.31% received two PIMs, and 4.69% received at least three PIMs according to the criteria (Table 2). Overall, estazolam, tramadol, and megestrol were the most used PIMs according to the 2019 Beers criteria, at 18.60%, 13.44, and 12.92%, respectively (Table 3).

Among the 1,009 older lung cancer outpatients with prescriptions in 2017, 361 (35.78%) outpatients were identified to have at least one PIM, and a total of 480 PIMs were detected by the 2019 Beers criteria. Of the patients with PIM prescriptions, 82.27% received one PIM, 11.36% received two PIMs, and 6.37% received at least three PIMs according to the criteria (Table 2). Overall, estazolam, tramadol, and megestrol were the most used PIMs according to the 2019 Beers criteria, at 21.25%, 15.70, and 10.62%, respectively (Table 3).

Among the 1,275 older lung cancer outpatients with prescriptions in 2018, 544 (42.67%) outpatients were identified to have at least one PIM, and a total of 723 PIMs were detected according to the 2019 Beers criteria. Of the patients with PIM prescriptions, 80.70% received one PIM, 15.13% received two PIMs, and 4.69% received at least three PIMs according to the criteria (Table 2). Overall, estazolam, tramadol, and megestrol were the most used PIMs according to the 2019 Beers criteria, at 22.44%, 17.47, and 9.34%, respectively (Table 3).

**Risk Factors for PIM Use**
PIM use, based on the 2019 Beers criteria, was the dependent variable in the logistic regression analysis (non-PIM use = 0, PIM use = 1). The logistic regression analysis indicated that age 75–79 (OR: 1.276 in Model 1, OR: 1.273 in Model 2), polypharmacy (OR: 2.587 in Model 1, OR: 2.672 in Model 2, OR: 2.678 in Model 3), and the irrational use of drugs (OR: 2.146 in Model 1, OR: 2.082 in Model 2, OR: 2.078 in Model 3) were positively
TABLE 1 | Basic characteristics of older lung cancer outpatients.

| Characteristic                  | Total                  | 2016 (N = 1,002) | 2017 (N = 1,009) | 2018 (N = 1,275) |
|--------------------------------|------------------------|------------------|------------------|------------------|
|                                | Total                  | PIM Group        | Non-PIM Group    | P Value          | PIM Group        | Non-PIM Group    | P Value          | PIM Group        | Non-PIM Group    | P Value          | PIM Group        | Non-PIM Group    | P Value          |
|                                |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| N (%)                          | 3,286                  | 320 (31.94)      | 682 (68.06)      | 0.434            | 361 (35.78)      | 648 (64.22)      | 0.626            | 544 (42.67)      | 731 (57.33)      | 0.677            |
| Sex, n (%)                     |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Male                           | 1,837 (55.90)          | 176 (55.00)      | 393 (57.62)      |                  | 206 (57.06)      | 380 (58.64)      |                  | 310 (56.99)      | 408 (55.81)      |                  |
| Female                         | 1,449 (44.10)          | 144 (45.00)      | 289 (42.36)      | 0.561            | 155 (42.94)      | 268 (41.36)      |                  | 234 (43.01)      | 323 (44.19)      |                  |
| Age, years (IQR), n (%)        | 65–69                  | 1,222 (37.19)    | 123 (38.44)      | 251 (36.80)      | 0.591            | 71 (68, 76)      | 0.001            | 72 (68, 76)      | 0.199            |
|                                |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Cancer type                    |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| SCLC                           | 127 (3.86)             | 10 (3.13)        | 29 (4.25)        | 0.390            | 10 (2.77)        | 37 (5.71)        | 0.034            | 29 (5.33)        | 53 (7.25)        | 0.167            |
| Non-PIM                        |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| PIM                            |                        |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |

DISCUSSION

To the best of our knowledge, this is the first study to assess the trends of polypharmacy and PIM use in older Chinese lung cancer outpatients with multimorbidity. Previous studies based on national representative surveys have shown an alarming increase in the polypharmacy trends in the United States (from 8.2% in associated with PIM use in older lung cancer outpatients. Older lung cancer patients with sleep disorders (OR: 11.408 in Model 1, OR: 11.433 in Model 2, OR: 11.158 in Model 3), anxiety or pulmonary disease.

Frontiers in Pharmacology | www.frontiersin.org 4 July 2022 | Volume 13 | Article 935764

For patients with multimorbidity. Previous studies based on national representative surveys have shown an alarming increase in the polypharmacy trends in the United States (from 8.2% in
1999 to 15% in 2012; Kantor et al., 2015), Sweden (from 16.9% in 2006 to 19.0% in 2014; Zhang et al., 2020), and France (from 44.9% in 2011 to 47.8% in 2019; Drusch et al., 2021), which are consistent with regional register-based studies on this period in the United Kingdom (a polypharmacy increase from 11.2% in 1995 to 22.8% in 2010; Guthrie et al., 2015) and those using the University Groningen IADB.nl prescription database in the Netherlands (showing an increase from 56.5% in 2012 to 58.2% in 2016; Oktora et al., 2021). Subjective measures, such as sleep diaries and anxiety and depression screening scales, also assist the diagnosis. As the diagnosis is determined, the use of drugs may be further increased (Hita-Yañez et al., 2013). In our study, the number of medications and diseases showed an increasing trend from 2016 to 2018. Therefore, the prevalence of polypharmacy increased in our study. Some studies in Europe and the United States have reported a decrease in the prevalence of PIMs (Ble et al., 2012; Hovstadius et al., 2014; Davidoff et al., 2015; Muhlack et al., 2018). With the popularization of Beers criteria, clinicians pay more attention to PIMs use in older patients; however, due to the increase of chronic diseases, the number of medications increased. This may be the reason that studies in the US indicate increased polypharmacy yet decrease in prevalence of PIMs use. However, one study in Ireland showed that the prevalence of PIM use rose from 32.6% in 1997 to 37.3% in 2012 (Moriarty et al., 2015). Our previous study showed an increasing trend of PIM use in older inpatients, from 71.17% in 2016 to 73.39% in 2018 (Tian et al., 2021). These results were similar to those of our present study, in which an increased prevalence of PIM use was observed in an older

| TABLE 2 | The number of PIMs used by older lung cancer outpatients. |
| Characteristic | 2016 | 2017 | 2018 |
|----------------|------|------|------|
| PIM prescription | 320 361 544 | 256 (80.00) 297 (82.27) 439 (80.70) | 49 (15.31) 41 (11.36) 66 (12.13) | 15 (4.69) 23 (6.37) 39 (7.17) |
| PIMs, n (%) | 1PIM | 2 PIMs | ≥3 PIMs |
|---------------|------|--------|--------|
| Estazolam | 72 (18.60) | Estazolam | 92 (21.25) | Estazolam | 149 (22.44) |
| Tramadol | 52 (13.44) | Tramadol | 68 (15.70) | Tramadol | 116 (17.47) |
| Megestrol | 50 (12.92) | Megestrol | 46 (10.62) | Ibuprofen | 62 (9.34) |
| Ibuprofen | 33 (8.53) | Ibuprofen | 36 (8.31) | Alprazolam | 51 (7.68) |
| Hydrochlorothiazide | 29 (7.49) | Hydrochlorothiazide | 34 (7.85) | Hydrochlorothiazide | 51 (7.68) |

PIM, potentially inappropriate medication.
TABLE 4 | Multivariate logistic regression analysis of factors associated with PIM use.

| Characteristic | OR   | 95% CI     | p Value | Characteristic | OR   | 95% CI     | p Value | Characteristic | OR   | 95% CI     | p Value |
|----------------|------|------------|---------|----------------|------|------------|---------|----------------|------|------------|---------|
| Year           |      |            |         |                |      |            |         |                |      |            |         |
| 2016           | References |           |         |                |      |            |         |                |      |            |         |
| 2017           | 1.069 | 0.855–1.335 | 0.559   |                |      |            |         |                |      |            |         |
| 2018           | 1.432 | 1.161–1.766 | 0.001   |                |      |            |         |                |      |            |         |
| Sex femal      |      |            |         |                |      |            |         |                |      |            |         |
| Age, y         |      |            |         |                |      |            |         |                |      |            |         |
| 65–69          | References |           |         |                |      |            |         |                |      |            |         |
| 70–74          | 0.793 | 0.639–0.983 | 0.034   |                |      |            |         |                |      |            |         |
| 75–79          | 1.276 | 1.016–1.602 | 0.036   |                |      |            |         |                |      |            |         |
| ≥80            | 1.040 | 1.146–1.525 | 0.790   |                |      |            |         |                |      |            |         |
| No. of diseases|      |            |         |                |      |            |         |                |      |            |         |
| 2              | References |           |         |                |      |            |         |                |      |            |         |
| 3–4            | 0.888 | 0.710–1.061 | 0.166   |                |      |            |         |                |      |            |         |
| ≥5             | 0.709 | 0.545–0.922 | 0.01    |                |      |            |         |                |      |            |         |
| No. of medications|          |            |         |                |      |            |         |                |      |            |         |
| 1–4            | References |           |         |                |      |            |         |                |      |            | <0.001 |
| ≥5             | 2.587 | 1.988–3.367 | <0.001  |                |      |            |         |                |      |            |         |
| No. of rational prescriptions|          |            |         |                |      |            |         |                |      |            |         |
| Rational prescriptions|          |            |         |                |      |            |         |                |      |            |         |
| Irrational prescriptions|          |            |         |                |      |            |         |                |      |            |         |
| Prescription expenditure|          |            |         |                |      |            |         |                |      |            |         |
| <500 CNY       | References |           |         |                |      |            |         |                |      |            |         |
| 500–1,000 CNY  | 0.486 | 0.383–0.617 | <0.001  |                |      |            |         |                |      |            |         |
| >1,000 CNY     | 0.419 | 0.336–0.521 | <0.001  |                |      |            |         |                |      |            | <0.001 |
| Type of chronic disease|          |            |         |                |      |            |         |                |      |            |         |
| Sleep disorder | 11.408| 9.061–14.362| <0.001  |                |      |            |         |                |      |            | <0.001 |
| Anxiety or depression|         |            |         |                |      |            |         |                |      |            |         |
| Pain           | 7.021 | 5.753–8.569 | <0.001  |                |      |            |         |                |      |            | <0.001 |
| Pulmonary infection COPD | 0.772 | 0.511–1.168 | 0.221   |                |      |            |         |                |      |            |         |
| COPD           | 0.772 | 0.511–1.168 | 0.221   |                |      |            |         |                |      |            |         |

PIM, potentially inappropriate medication; IQR, interquartile range; CNY, Chinese yuan; COPD, chronic obstructive pulmonary disease.
Model 1: Multivariate logistic regression analysis of factors associated with PIM use in older lung cancer outpatients.
Model 2: Multivariate logistic regression analysis of factors associated with PIM use in older lung cancer outpatients adjusted by year, sex, and age.
Model 3: Multivariate logistic regression analysis of factors associated with PIM use in older lung cancer outpatients adjusted by year.

lung cancer patient population. Because polypharmacy is associated with an increased risk of inappropriate prescriptions, the prevalence of polypharmacy and PIM use in our studies were related, showing an increasing trend.

Our study was the first repeated cross-sectional study on the prevalence and risk factors for PIM use in older Chinese lung cancer outpatients. A United States study reported that the monthly prevalence of any PIM prior to cancer diagnosis was similar across all three cancer cohorts (breast cancer, colon cancer, and lung cancer), hovering between 37 and 40%, whereas PIM prevalence sharply increased in the first few months following the lung cancer (stage I–II) diagnosis. This may be when the lung cancer is diagnosed, the anti-emetics, antispasmodic drugs, and hydrochlorothiazide were usually used (Lund et al., 2018). The prevalence of PIM use in older lung cancer patients was higher than that in patients with the other two cancers according to the 2012 Beers criteria. The prevalence of PIM use, according to the 2019 Beers criteria, in our study was 37.28% over 3 years, which was higher than that reported in another study on the prevalence of PIM use among older Chinese cancer outpatients which were outside of palliative care and hospice service (32.65%; Tian et al., 2022a). Our previous study found that lung cancer was positively associated with PIM use in older cancer outpatients, which explains the higher prevalence of PIM use in this study. It is of great significance to study...
the high-risk population of PIMs use and provide targeted drug intervention for the follow-up. The prevalence of PIM use in our study was slightly higher than that of the older advanced NSCLC patients who underwent epidermal growth factor receptor tyrosine kinase inhibitor in Japan, with a prevalence of 31.9% (Hakozaki et al., 2021), and lower than that in older NSCLC and SCLC patients at the end of life in the Netherlands, at 45% (Ham et al., 2021). The high prevalence of PIM use in these end-of-life patients is explained by the fact that these patients are usually in serious condition, both physically and mentally, and are thus highly willing to take more medications. Another potential reason for this difference is that the adverse outcomes in older lung cancer patients at the end of life are highly associated with PIM use; the poor clinical outcome of these patients further aggravates the prevalence of PIM use (Mohamed et al., 2020; Chen et al., 2021).

In our present study, the two most frequent PIMs in older Chinese lung cancer outpatients were estazolam and tramadol over the 3 years. Sleep disorders can be both complex and common in older age, although reported prevalence varies (Hishikawa et al., 2017; Patel et al., 2018). Although research on the causal effect of sleep disorders on lung cancer incidence is still lacking, many lung cancer patients were also diagnosed with sleep disorders or pain in our study. Use of estazolam, a benzodiazepine, increases the risk of falls in older adults and co-prescribing of opioids exponentsiates this risk (Niznik et al., 2022). Meanwhile, long-term use of benzodiazepines will increase the risk of respiratory depression and overdose with administration of benzodiazepine in older patients with sleep disorders. Pain is the most common symptom that occurs in 40% of lung cancer patients (Iwase et al., 2015), which can arise as a result of local effects (i.e., hemorrhaging into the tumor, obstruction/perforation of the lungs) or anti-cancer treatments, such as chemotherapy (Tang et al., 2021). The treatment of cancer pain mostly utilizes the three-step “ladder” treatment principle proposed by the World Health Organization; tramadol is commonly used for mild and moderate pain (Tian et al., 2022b). Although the analgesic effect of tramadol is good, its side effects induce syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia, and these risks are higher in older adults, which limits the clinical application of this medication (Li et al., 2021). Older patients with lung cancer need help with sleeping especially if in pain, especially in elderly patients with lower pain threshold levels. Therefore, sedative hypnotic drugs are taken more frequently than elderly patients without lung cancer. In order to ensure the risk-benefit balance of drug use in this population, it is of great significance to develop models that meet the PK/PD characteristics of this population to evaluate the appropriate medication use rather than keeping to a specific number of medicines in this fragile population. According to the logistic regression analysis, risk factors for PIM use were the same among the three models: 75–79 years of age, polypharmacy, irrational use of drugs and lung cancer accompanied by sleep disorders, anxiety or depression, or pain. However, some pulmonary diseases, such as pulmonary infection and COPD, were not risk factors for PIM use. Therefore, we suggest reducing the prescription of unnecessary medications and that doctors or pharmacists carefully perform medication reconciliation for older lung cancer outpatients taking multiple medications.

Several limitations of this study should be noted. First, this study only investigated 3 years of data in China, and more years of data are needed to determine long-term trends of polypharmacy and PIM use in older lung cancer outpatients with multimorbidity. Second, outpatients attending tertiary hospitals were the main focus of the study; thus, lung cancer outpatients who were in nursing homes and communities were not evaluated. In addition, the research aimed at only one area population may have limited popularization.

**CONCLUSION**

This study investigated the trends of polypharmacy and PIM use in older lung cancer outpatients with multimorbidity in China based on the 2019 Beers criteria. The prevalence of polypharmacy and PIM use showed an increasing trend in older Chinese lung cancer outpatients, and age 75–79, polypharmacy, irrational use of drugs, and lung cancer accompanied by sleep disorders, anxiety or depression, or pain were risk factors for PIM use.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Materials; further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by this study protocol, which was approved by the Sichuan University West China Hospital Research Ethics Board. Written informed consent from participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

Conception and design: FT. Administrative support: FT. Provision of study materials or patients: FT, MZ. Collection and assembly of data: FT, XC. Data analysis and interpretation: FT and ZC. Manuscript writing: all authors. Final approval of manuscript: all authors.

**FUNDING**

This work was supported by the Sichuan Science and Technology Program (Project number 2022JDR0326).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.935764/full#supplementary-material.
Tian, F., Liao, S., Chen, Z., and Xu, T. (2021). The Prevalence and Risk Factors of Potentially Inappropriate Medication Use in Older Chinese Inpatients with Multimorbidity and Polypharmacy: a Cross-Sectional Study. *Ann. Transl. Med.* 9 (18), 1483. doi:10.21037/atm-21-4238

Tian, F., Yang, R., Chen, Z., Duan, X., and Yuan, P. (2022b). The Prevalence and Factors Associated with Potentially Inappropriate Medication Use in Chinese Older Outpatients with Cancer with Multimorbidity. *J. Geriatr. Oncol.* 2022 (22), S18790021–S187940682. doi:10.1016/j.jgo.2022.02.006

Tian, F., Zhao, M., Chen, Z., and Yang, R. (2022a). Prescription of Potentially Inappropriate Medication Use in Older Cancer Outpatients with Multimorbidity: Concordance Among the Chinese, AGS/Beers, and STOPP Criteria. *Front. Pharmacol.* 13, 857811. doi:10.3389/fphar.2022.857811

Torre, L. A., Siegel, R. L., and Jemal, A. (2016). Lung Cancer Statistics. *Adv. Exp. Med. Biol.* 893, 1–19. doi:10.1007/978-3-319-24223-1_1

Wallace, E., McDowell, R., Bennett, K., Fahey, T., and Smith, S. M. (2017). Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study. *J. Gerontol. A Biol. Sci. Med. Sci.* 72 (2), 271–277. doi:10.1093/gerona/glw140

Weng, M. C., Tsai, C. F., Sheu, K. L., Lee, Y. T., Lee, H. C., Tzeng, S. L., et al. (2013). The Impact of Number of Drugs Prescribed on the Risk of Potentially Inappropriate Medication Among Outpatient Older Adults with Chronic Diseases. *QJM* 106, 1009–1015. doi:10.1093/qjmed/hct141

WHO (2022). Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer (Accessed March 23, 2022).

Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et al. (2014). International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients with Cancer. *J. Clin. Oncol.* 32, 2595–2603. doi:10.1200/JCO.2013.54.8347

Zhang, N., Sundquist, J., Sundquist, K., and Li, J. (2020). An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study. *Front. Pharmacol.* 11, 326. doi:10.3389/fphar.2020.00326

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tian, Chen, Chen and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.